154 related articles for article (PubMed ID: 10417773)
1. Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using (125)I-labeled anti-endoglin monoclonal antibodies.
Tabata M; Kondo M; Haruta Y; Seon BK
Int J Cancer; 1999 Aug; 82(5):737-42. PubMed ID: 10417773
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
Takahashi N; Haba A; Matsuno F; Seon BK
Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
[TBL] [Abstract][Full Text] [Related]
3. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
Seon BK; Matsuno F; Haruta Y; Kondo M; Barcos M
Clin Cancer Res; 1997 Jul; 3(7):1031-44. PubMed ID: 9815781
[TBL] [Abstract][Full Text] [Related]
4. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies.
Matsuno F; Haruta Y; Kondo M; Tsai H; Barcos M; Seon BK
Clin Cancer Res; 1999 Feb; 5(2):371-82. PubMed ID: 10037187
[TBL] [Abstract][Full Text] [Related]
5. Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: differences in growth rate and therapeutic response between tumors growing at different sites.
Tsujie M; Uneda S; Tsai H; Seon BK
Int J Oncol; 2006 Nov; 29(5):1087-94. PubMed ID: 17016638
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice.
Tsujie M; Tsujie T; Toi H; Uneda S; Shiozaki K; Tsai H; Seon BK
Int J Cancer; 2008 May; 122(10):2266-73. PubMed ID: 18224682
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis and metastasis marker of human tumors.
Seon BK; Takahashi N; Haba A; Matsuno F; Haruta Y; She XW; Harada N; Tsai H
Rinsho Byori; 2001 Oct; 49(10):1005-13. PubMed ID: 11769465
[TBL] [Abstract][Full Text] [Related]
8. Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells.
She X; Matsuno F; Harada N; Tsai H; Seon BK
Int J Cancer; 2004 Jan; 108(2):251-7. PubMed ID: 14639611
[TBL] [Abstract][Full Text] [Related]
9. Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature.
Uneda S; Toi H; Tsujie T; Tsujie M; Harada N; Tsai H; Seon BK
Int J Cancer; 2009 Sep; 125(6):1446-53. PubMed ID: 19533687
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin.
Shiozaki K; Harada N; Greco WR; Haba A; Uneda S; Tsai H; Seon BK
Cancer Immunol Immunother; 2006 Feb; 55(2):140-50. PubMed ID: 15856228
[TBL] [Abstract][Full Text] [Related]
11. Targeting angiogenesis for radioimmunotherapy with a
Ehlerding EB; Lacognata S; Jiang D; Ferreira CA; Goel S; Hernandez R; Jeffery JJ; Theuer CP; Cai W
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):123-131. PubMed ID: 28821931
[TBL] [Abstract][Full Text] [Related]
12. Facilitation of endoglin-targeting cancer therapy by development/utilization of a novel genetically engineered mouse model expressing humanized endoglin (CD105).
Toi H; Tsujie M; Haruta Y; Fujita K; Duzen J; Seon BK
Int J Cancer; 2015 Jan; 136(2):452-61. PubMed ID: 24866768
[TBL] [Abstract][Full Text] [Related]
13. Endoglin-targeted cancer therapy.
Seon BK; Haba A; Matsuno F; Takahashi N; Tsujie M; She X; Harada N; Uneda S; Tsujie T; Toi H; Tsai H; Haruta Y
Curr Drug Deliv; 2011 Jan; 8(1):135-43. PubMed ID: 21034418
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy and dose-limiting toxicity of Auger-electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: evaluation of 125I- vs. 131I-labeled CO17-1A in a human colorectal cancer model.
Behr TM; Sgouros G; Vougiokas V; Memtsoudis S; Gratz S; Schmidberger H; Blumenthal RD; Goldenberg DM; Becker W
Int J Cancer; 1998 May; 76(5):738-48. PubMed ID: 9610734
[TBL] [Abstract][Full Text] [Related]
15. Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model.
Fonsatti E; Jekunen AP; Kairemo KJ; Coral S; Snellman M; Nicotra MR; Natali PG; Altomonte M; Maio M
Clin Cancer Res; 2000 May; 6(5):2037-43. PubMed ID: 10815930
[TBL] [Abstract][Full Text] [Related]
16. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
17. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct.
Pavlinkova G; Booth BJ; Batra SK; Colcher D
Clin Cancer Res; 1999 Sep; 5(9):2613-9. PubMed ID: 10499640
[TBL] [Abstract][Full Text] [Related]
18. Tumor vascular homing endgolin-targeted radioimmunotherapy in hepatocellular carcinoma.
Duan CL; Hou GH; Liu YP; Liang T; Song J; Han JK; Zhang C
Tumour Biol; 2014 Dec; 35(12):12205-15. PubMed ID: 25164610
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy.
Burrows FJ; Derbyshire EJ; Tazzari PL; Amlot P; Gazdar AF; King SW; Letarte M; Vitetta ES; Thorpe PE
Clin Cancer Res; 1995 Dec; 1(12):1623-34. PubMed ID: 9815965
[TBL] [Abstract][Full Text] [Related]
20. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
